Characterization of ovulation inhibition of a new vaginal delivery system (EVE 112, Evestra/Germany) containing etonogestrel and ethinylestradiol an open label, single centre, comparative, parallel-group study in healthy females of childbearing potential
Phase of Trial: Phase II
Latest Information Update: 10 Mar 2017
At a glance
- Drugs Ethinylestradiol/etonogestrel (Primary)
- Indications Pregnancy
- Focus Therapeutic Use
- Sponsors Evestra
- 10 Mar 2017 Status changed from recruiting to completed.
- 16 Apr 2016 Planned number of patients changed from 50 to 88.
- 14 Mar 2016 New trial record